A Phase 1 interventional study of VXA-G1.1-NN and VXA-G2.4-NS in Norovirus Infections, sponsored by Vaxart. Completed at 5 sites in South Africa. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Vaxart · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the safety and tolerability of an oral bivalent GI.1/GII.4 norovirus vaccine administration in healthy lactating female participants and to assess the short-term immunogenicity of oral bivalent GI.1/GII.4 norovirus vaccine administration in healthy lactating female participants and its association with the immunogenicity response in breastmilk.
20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.
This study's enrollment of 76 is close to the median of 71 across 18 interventional studies indexed under Caliciviridae Infections.
Browse Caliciviridae Infections studies →Vaxart is the lead sponsor of 23 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The nursing infant is the product of a singleton pregnancy AND does not have any of the following:
Exclusion Criteria:
History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:
a. Any history of:
i.
ii. Malabsorption
iii. Pancreatobiliary disorders
iv. Inflammatory bowel disease
v. Irritable bowel disease
vi. Hiatal hernia
vii. Surgical resection
b. History of diagnosis or treatment in past 5 years of:
i. Esophageal or gastric motility disorder
ii. Gastroesophageal reflux disease (GERD) - Will allow for participants with a history of pregnancy-related GERD if fully resolved for >3 months and no other history of GERD diagnosis
iii. Peptic ulcer
iv. Cholecystectomy
Any of the following history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia:
i. Recent surgery other than fully healed cesarean delivery or excision/ of cutaneous lesions
ii. Immobility (confined to bed or wheelchair for 3 or more successive days)
iii. Head trauma with loss of consciousness or documented brain injury
iv. Receipt of anticoagulants for prophylaxis of thrombosis
v. Recent infection including hospitalization for COVID-19 related illness
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a medium dose of bivalent VXA-G1.1-NN and VXA-GII.4-NS as an oral tablet on Day 1.
Biological: VXA-G1.1-NN · Biological: VXA-G2.4-NS
Participants will receive a high dose of bivalent VXA-G1.1-NN and VXA-GII.4-NS as an oral tablet on Day 1.
Biological: VXA-G1.1-NN · Biological: VXA-G2.4-NS
Participants will receive matching placebo orally on Day 1.
Biological: Placebo Tablets
Oral tablets.
Also known as: GI.1
Oral tablets.
Also known as: GII.4
Oral tablets.
Number of Participants (Mothers) With Any Solicited Symptoms of Reactogenicity for 1 Week Following Trial Dose
Solicited symptoms of reactogenicity were predefined adverse events (AEs) for which the participant was specifically questioned, and which were noted by the participant in their solicited symptom diary, including: fever (any temperature 100°F or higher), headache, myalgia (muscle pain), abdominal pain, anorexia (defined as not eating), nausea, vomiting, diarrhea, and malaise/fatigue. The severity of each solicited symptom of reactogenicity was graded by the participant as mild, moderate, severe or life-threatening.
Time frame: 1 week post study dose (8 days)
Number of Participants (Mothers) With Unsolicited Treatment-emergent Adverse Events (TEAEs)
TEAEs:AEs that began after start of an investigational product or an already present event that worsens in intensity or frequency following intervention.An AE considered serious (SAE) if,in view of Investigator or Sponsor,it resulted in death,life-threatening AE,inpatient hospitalization/prolongation of hospitalization,persistent or significant incapacity or disability disrupting normal life functions,congenital anomaly/birth defect,or an important medical event which based upon medical judgment may have jeopardized participant and required intervention to prevent 1 of outcomes.AESIs:serious/non-serious AEs of scientific and medical concern with potential immune mediated conditions and events associated with thrombosis and thrombocytopenia.NOCI:diagnosis post-enrollment and vaccination of new chronic medical condition,including those controllable by medication.An AE was unsolicited if it did not fulfill conditions prelisted in eCRF in terms of diagnosis/onset window post-vaccination.
Time frame: 4 weeks post dose (29 days)
Geometric Mean Concentration (GMC) of Serum Viral Protein 1 (VP1) Specific (G1.1) Immunoglobulin A (IgA) on Days 1, 8 and 29
GMC of serum VP1 specific (G1.1) IgA was measured by Meso Scale Discovery (MSD) assay. Assay was measured in an arbitrary unit per milliliter (AU/mL).
Time frame: Days 1, 8 and 29
GMC of Serum VP1 Specific (G2.4) IgA on Days 1, 8 and 29
GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.
Time frame: Days 1, 8 and 29
Geometric Mean Fold Rise (GMFR) From Day 1 to Day 8 of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 8
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 8
GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 29
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 29
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 8
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 8
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 29
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 29
Number of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgA
A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29 and 180
Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgA
A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29 and 180
GMC of Breastmilk VP1 Specific (G1.1) IgA on Days 1, 8 and 29
GMC of breastmilk VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in Relative Light Unit per microgram (RLU)/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
Time frame: Days 1, 8, and 29
GMC of Breastmilk VP1 Specific (G2.4) IgA on Days 1, 8 and 29
GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
Time frame: Days 1, 8 and 29
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 8
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 8
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 8
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 8
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 29
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 29
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 29
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 29
Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G1.1) IgA
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibody compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, 60 and 180
Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G2.4) IgA
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, 60 and 180
Number of Participants With SAEs, AESIs and NOCIs Through 12 Months Post Dose
An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset window post-vaccination. An AESIs serious or nonserious) is one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor can be appropriate. NOCIs was defined as diagnosis post-enrollment and vaccination of a new medical condition, which is chronic in nature, including those potentially controllable by medication. Only unsolicited SAEs, AESI and NOCIs data was planned to be collected and assessed for the assessment of this OM and solicited SAEs, AESIs and NOCIs was out of the scope of assessment. Participants with unsolicited SAEs, AESIs and NOCIs throughout the trial were reported in this outcome measure.
Time frame: Up to 12 months
GMC of Serum VP1 Specific (G1.1) IgA on Day 180
GMC of serum VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in AU/mL.
Time frame: Day 180
GMC of Serum VP1 Specific (G2.4) IgA on Day 180
GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.
Time frame: Day 180
GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 180
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 180
GMC of Breastmilk VP1 Specific (G1.1) IgA on Days 60 and 180
GMC of breastmilkVP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
Time frame: Days 60 and 180
GMC of Breastmilk VP1 Specific (G2.4) IgA on Days 60 and 180
GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
Time frame: Days 60 and 180
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 60
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 60
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 60
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 60
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 180
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Day 180
GMC of Serum VP1 Specific (G1.1) Immunoglobulin G (IgG) on Days 1, 8, 29, and 180
GMC of serum VP1 specific (G1.1) IgG was measured by MSD assay. Assay is measured in AU/mL.
Time frame: Days 1, 8, 29, and 180
GMC of Serum VP1 Specific (G2.4) IgG on Days 1, 8, 29, and 180
GMC of serum VP1 specific (G2.4) IgG was measured by MSD assay. Assay is measured in AU/mL.
Time frame: Days 1, 8, 29 and 180
GMFR of Serum VP1 Specific (G1.1) IgG From Day 1 to Days 8, 29, and 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: From Day 1 to Days 8, 29, and 180
GMFR of Serum VP1 Specific (G2.4) IgG From Day 1 to Days 8, 29, and 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: From Day 1 to Days 8, 29, and 180
Number of Participants Who Achieved a 2-fold, 3-fold, and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgG
A 2, 3, and 4-fold rise represents the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, and 180
Number of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgG
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, and 180
Geometric Mean Titer (GMT) of Serum Blocking Titers 50 (BT50) (G1.1) on Days 1, 8, 29, and 180
Serum BT50 (G1.1) through 6 months after trial drug dose was measured by histo-blood group antigen (HBGA) assay. Blood samples were collected at different timepoints throughout the trial.
Time frame: Days 1, 8, 29, and 180
GMT of Serum BT50 (G2.4) on Days 1, 8, 29, and 180
Serum BT50 (G2.4) through 6 months after trial drug dose was measured by HBGA assay. Blood samples were collected at different timepoints throughout the trial.
Time frame: Days 1, 8, 29, and 180
GMFR of Serum BT50 (G1.1) From Day 1 to Days 8, 29 and 180
The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Days 8, 29, and 180
GMFR of Serum BT50 (G2.4) From Day 1 to Days 8, 29 and 180
The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Days 8, 29 and 180
Number of Participants Who Achieved 2-fold, 3-fold, and 4-fold GMT Rise in Serum VP1 Specific (G1.1) IgG
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, and 180
Number of Participants With 2-fold, 3-fold and 4-fold GMT Rise in Serum VP1 Specific IgG (G2.4)
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, and 180
GMC of Nasal VP1 Specific (G1.1) IgA
GMC of nasal VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in microgram per milligram (µg/mg).
Time frame: Days 1, 8, 29, 60, and 180
GMC of Nasal VP1 Specific (G2.4) IgA
GMC of nasal VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.
Time frame: Days 1, 8, 29, 60, and 180
GMFR of Nasal VP1 Specific (GI.I) IgA From Day 1 to Days 8, 29, 60 and 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Days 8, 29, 60 and 180
GMFR of Nasal VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60 and 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Days 8, 29, 60 and 180
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G1.1)
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, 60 and 180
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G2.4)
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, 60 and 180
GMC of Saliva VP1 Specific (G1.1) IgA
GMC of saliva VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.
Time frame: Days 1, 8, 29, 60, and 180
GMC of Saliva VP1 Specific (G2.4) IgA
GMC of saliva VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.
Time frame: Days 1, 8, 29, 60, and 180
GMFR of Saliva VP1 Specific (G1.1) IgA From Day 1 to Days 8, 29, 60 and 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Days 8, 29, 60, and 180
GMFR of Saliva VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60, and 180
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: From Day 1 to Days 8, 29, 60, and 180
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G1.1)
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, 60 and 180
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G2.4)
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29, 60 and 180
GMC of Infant Stool VP1 Specific (G1.1) IgA
GMC of infant stool VP1 specific (G1.1) IgA was measured by Enzyme-linked immunosorbent assay (ELISA). Assay is measured in mg/gm.
Time frame: Days 1, 29 and 60
GMC of Infant Stool VP1 Specific (G2.4) IgA
GMC of infant stool VP1 specific (G2.4) IgA was measured by ELISA. Assay is measured in mg/gm.
Time frame: Days 1, 29 and 60
GMFR of Infant Stool VP1 Specific (G1.1) IgA From Day 1 to Days 29 and 60
GMFR was measured by ELISA. The fold rise was calculated per participant (infant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Days 29 and 60
GMFR of Infant Stool VP1 Specific (G2.4) IgA From Day 1 to Days 29 and 60
GMFR was measured by ELISA. The fold rise was calculated per infant (participant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
Time frame: Day 1 to Days 29 and 60
Number of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G1.1)
A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 29 and 60
Number of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G2.4)
A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
Time frame: Days 1, 8, 29 and 60
Number of Participants With Norovirus Acute Gastroenteritis
Data was not collected for this outcome measure.
Time frame: From first dose up to Day 365
A total of 76 mother participants were enrolled between October 2023 and December 2024 in South Africa.
| Milestone | Arm 1 Medium Bivalent Dose | Arm 2 High Bivalent Dose | Arm 3 Placebo |
|---|---|---|---|
| Started | 30 | 30 | 16 |
| Mothers started | 30 | 30 | 16 |
| Infants started | 30 | 30 | 16 |
| Completed | 26 | 29 | 12 |
| Not completed | 4 | 1 | 4 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 | 2 |
Solicited symptoms of reactogenicity were predefined adverse events (AEs) for which the participant was specifically questioned, and which were noted by the participant in their solicited symptom diary, including: fever (any temperature 100°F or higher), headache, myalgia (muscle pain), abdominal pain, anorexia (defined as not eating), nausea, vomiting, diarrhea, and malaise/fatigue. The severity of each solicited symptom of reactogenicity was graded by the participant as mild, moderate, severe or life-threatening.
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Mild | 15 | 8 | 5 |
| Moderate | 1 | 5 | 1 |
| Severe | 0 | 0 | 0 |
| Life-threatening | 0 | 0 | 0 |
TEAEs:AEs that began after start of an investigational product or an already present event that worsens in intensity or frequency following intervention.An AE considered serious (SAE) if,in view of Investigator or Sponsor,it resulted in death,life-threatening AE,inpatient hospitalization/prolongation of hospitalization,persistent or significant incapacity or disability disrupting normal life functions,congenital anomaly/birth defect,or an important medical event which based upon medical judgment may have jeopardized participant and required intervention to prevent 1 of outcomes.AESIs:serious/non-serious AEs of scientific and medical concern with potential immune mediated conditions and events associated with thrombosis and thrombocytopenia.NOCI:diagnosis post-enrollment and vaccination of new chronic medical condition,including those controllable by medication.An AE was unsolicited if it did not fulfill conditions prelisted in eCRF in terms of diagnosis/onset window post-vaccination.
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| TEAEs | 3 | 3 | 2 |
| SAEs | 0 | 0 | 0 |
| AESIs | 0 | 0 | 0 |
| NOCIs | 0 | 0 | 0 |
GMC of serum VP1 specific (G1.1) IgA was measured by Meso Scale Discovery (MSD) assay. Assay was measured in an arbitrary unit per milliliter (AU/mL).
| AU/mL | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| Day 1 | 1050560.6 ± 1.3 | 1625693.1 ± 1.4 | 1209786.5 ± 1.2 |
| Day 8 | 3007539.8 ± 1.4 | 4608961.1 ± 1.3 | 1291836.6 ± 1.3 |
| Day 29 | 2065978.9 ± 1.3 | 2822260.3 ± 1.3 | 1421687.4 ± 1.3 |
GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.
| AU/mL | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 217289.1 ± 1.4 | 233243.3 ± 1.4 | 211741.7 ± 1.3 |
| Day 8 | 414338.2 ± 1.3 | 667484.3 ± 1.4 | 235517.7 ± 1.3 |
| Day 29 | 350427.7 ± 1.4 | 491546.9 ± 1.3 | 260989.1 ± 1.4 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Geometric Mean Fold Rise (GMFR) From Day 1 to Day 8 of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 8 | 2.7 ± 1.2 | 3.0 ± 1.2 | 1.1 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 29 | 1.8 ± 1.2 | 1.9 ± 1.2 | 1.1 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 8 | 1.9 ± 1.2 | 2.9 ± 1.2 | 1.1 ± 1.2 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 29 | 1.5 ± 1.1 | 2.1 ± 1.1 | 1.1 ± 1.2 |
A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 12 | 19 | 1 |
| Day 8: 3-fold | 11 | 14 | 1 |
| Day 8: 4-fold | 10 | 13 | 1 |
| Day 29: 2-fold | 9 | 17 | 2 |
| Day 29: 3-fold | 8 | 9 | 2 |
| Day 29: 4-fold | 6 | 4 | 2 |
| Day 180: 2-fold | 4 | 3 | 2 |
| Day 180: 3-fold | 3 | 2 | 1 |
| Day 180: 4-fold | 2 | 1 | 1 |
A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 11 | 17 | 1 |
| Day 8: 3-fold | 8 | 11 | 1 |
| Day 8: 4-fold | 7 | 10 | 1 |
| Day 29: 2-fold | 9 | 13 | 2 |
| Day 29: 3-fold | 5 | 7 | 1 |
| Day 29: 4-fold | 3 | 5 | 1 |
| Day 180: 2-fold | 2 | 4 | 2 |
| Day 180: 3-fold | 1 | 4 | 2 |
| Day 180: 4-fold | 1 | 2 | 2 |
GMC of breastmilk VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in Relative Light Unit per microgram (RLU)/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
| RLU/µg of total IgA | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 26300.4 ± 1.2 | 26309.0 ± 1.3 | 29393.5 ± 1.2 |
| Day 8 | 36747.1 ± 1.2 | 42476.5 ± 1.2 | 30427.5 ± 1.2 |
| Day 29 | 52017.9 ± 1.3 | 61663.9 ± 1.2 | 31963.7 ± 1.2 |
GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
| RLU/µg of total IgA | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 75811.2 ± 1.3 | 40270.6 ± 1.3 | 79636.1 ± 1.5 |
| Day 8 | 83208.0 ± 1.3 | 67097.9 ± 1.3 | 87120.3 ± 1.5 |
| Day 29 | 114825.2 ± 1.3 | 107289.5 ± 1.4 | 78850.3 ± 1.5 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 8 | 1.4 ± 1.1 | 1.6 ± 1.1 | 1.1 ± 1.2 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 8 | 1.1 ± 1.1 | 1.6 ± 1.1 | 1.1 ± 1.2 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 29 | 2.0 ± 1.2 | 2.3 ± 1.2 | 1.1 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 29 | 1.5 ± 1.2 | 2.7 ± 1.2 | 1.0 ± 1.3 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibody compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 6 | 11 | 0 |
| Day 8: 3-fold | 4 | 7 | 0 |
| Day 8: 4-fold | 3 | 4 | 0 |
| Day 29: 2-fold | 10 | 16 | 1 |
| Day 29: 3-fold | 6 | 11 | 1 |
| Day 29: 4-fold | 6 | 7 | 1 |
| Day 60: 2-fold | 8 | 12 | 1 |
| Day 60: 3-fold | 6 | 7 | 0 |
| Day 60: 4-fold | 5 | 5 | 0 |
| Day 180: 2-fold | 6 | 6 | 2 |
| Day 180: 3-fold | 5 | 4 | 2 |
| Day 180: 4-fold | 5 | 3 | 1 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 3 | 12 | 0 |
| Day 8: 3-fold | 1 | 6 | 0 |
| Day 8: 4-fold | 0 | 3 | 0 |
| Day 29: 2-fold | 7 | 15 | 0 |
| Day 29: 3-fold | 3 | 10 | 0 |
| Day 29: 4-fold | 2 | 10 | 0 |
| Day 60: 2-fold | 7 | 12 | 0 |
| Day 60: 3-fold | 4 | 11 | 0 |
| Day 60: 4-fold | 4 | 8 | 0 |
| Day 180: 2-fold | 2 | 11 | 1 |
| Day 180: 3-fold | 1 | 7 | 0 |
| Day 180: 4-fold | 1 | 5 | 0 |
An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset window post-vaccination. An AESIs serious or nonserious) is one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor can be appropriate. NOCIs was defined as diagnosis post-enrollment and vaccination of a new medical condition, which is chronic in nature, including those potentially controllable by medication. Only unsolicited SAEs, AESI and NOCIs data was planned to be collected and assessed for the assessment of this OM and solicited SAEs, AESIs and NOCIs was out of the scope of assessment. Participants with unsolicited SAEs, AESIs and NOCIs throughout the trial were reported in this outcome measure.
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|---|---|---|
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
| AESIs | 0 | 0 | 0 | 0 | 0 | 0 |
| NOCIs | 0 | 0 | 0 | 0 | 0 | 0 |
GMC of serum VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in AU/mL.
| AU/mL | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMC of Serum VP1 Specific (G1.1) IgA on Day 180 | 1276858.6 ± 1.4 | 1344498.0 ± 1.3 | 1187410.4 ± 1.3 |
GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.
| AU/mL | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMC of Serum VP1 Specific (G2.4) IgA on Day 180 | 230142.5 ± 1.3 | 264313.3 ± 1.4 | 286679.6 ± 1.4 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 180 | 1.1 ± 1.2 | 1.0 ± 1.2 | 1.0 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 180 | 1.0 ± 1.1 | 1.3 ± 1.1 | 1.3 ± 1.2 |
GMC of breastmilkVP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
| RLU/µg of total IgA | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 60 | 38202.5 ± 1.3 | 39691.9 ± 1.2 | 22119.3 ± 1.2 |
| Day 180 | 29484.2 ± 1.3 | 29964.5 ± 1.2 | 23367.0 ± 1.3 |
GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.
| RLU/µg of total IgA | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 60 | 91060.2 ± 1.3 | 69170.5 ± 1.3 | 58705.8 ± 1.5 |
| Day 180 | 62361.5 ± 1.3 | 62051.1 ± 1.4 | 59187.9 ± 1.5 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 60 | 1.5 ± 1.2 | 1.6 ± 1.2 | 0.8 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 60 | 1.3 ± 1.2 | 1.6 ± 1.2 | 0.8 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 180 | 1.1 ± 1.2 | 1.1 ± 1.2 | 0.8 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 180 | 0.8 ± 1.2 | 1.5 ± 1.2 | 0.8 ± 1.2 |
GMC of serum VP1 specific (G1.1) IgG was measured by MSD assay. Assay is measured in AU/mL.
| AU/mL | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 3397392.0 ± 1.3 | 1964195.4 ± 1.3 | 2765544.4 ± 1.4 |
| Day 8 | 4985139.4 ± 1.2 | 3678526.6 ± 1.3 | 3109431.7 ± 1.3 |
| Day 29 | 6548114.2 ± 1.3 | 6113406.5 ± 1.2 | 3386464.1 ± 1.4 |
| Day 180 | 4590720.0 ± 1.3 | 3044433.6 ± 1.2 | 3753633.6 ± 1.4 |
GMC of serum VP1 specific (G2.4) IgG was measured by MSD assay. Assay is measured in AU/mL.
| AU/mL | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 893913.0 ± 1.3 | 641462.6 ± 1.2 | 605754.7 ± 1.4 |
| Day 8 | 962779.9 ± 1.3 | 1013436.9 ± 1.2 | 679718.6 ± 1.3 |
| Day 29 | 916270.9 ± 1.3 | 1261314.2 ± 1.2 | 673043.6 ± 1.3 |
| Day 180 | 740190.3 ± 1.3 | 808781.1 ± 1.2 | 690756.2 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 1.6 ± 1.1 | 1.8 ± 1.1 | 1.1 ± 1.2 |
| From Day 1 to Day 29 | 2.1 ± 1.2 | 2.8 ± 1.2 | 1.2 ± 1.2 |
| From Day 1 to Day 180 | 1.5 ± 1.2 | 1.5 ± 1.2 | 1.4 ± 1.2 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 1.1 ± 1.1 | 1.6 ± 1.1 | 1.1 ± 1.1 |
| From Day 1 to Day 29 | 1.1 ± 1.1 | 1.9 ± 1.1 | 1.0 ± 1.2 |
| From Day 1 to Day 180 | 0.9 ± 1.2 | 1.2 ± 1.2 | 1.1 ± 1.2 |
A 2, 3, and 4-fold rise represents the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 6 | 10 | 1 |
| Day 8: 3-fold | 4 | 6 | 1 |
| Day 8: 4-fold | 4 | 5 | 1 |
| Day 29: 2-fold | 9 | 19 | 2 |
| Day 29: 3-fold | 6 | 14 | 2 |
| Day 29: 4-fold | 5 | 10 | 2 |
| Day 180: 2-fold | 8 | 11 | 5 |
| Day 180: 3-fold | 5 | 7 | 3 |
| Day 180: 4-fold | 4 | 5 | 3 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 0 | 8 | 1 |
| Day 8: 3-fold | 0 | 4 | 1 |
| Day 8: 4-fold | 0 | 3 | 1 |
| Day 29: 2-fold | 3 | 11 | 1 |
| Day 29: 3-fold | 0 | 7 | 1 |
| Day 29: 4-fold | 0 | 4 | 1 |
| Day 180: 2-fold | 2 | 9 | 3 |
| Day 180: 3-fold | 1 | 3 | 2 |
| Day 180: 4-fold | 0 | 2 | 2 |
Serum BT50 (G1.1) through 6 months after trial drug dose was measured by histo-blood group antigen (HBGA) assay. Blood samples were collected at different timepoints throughout the trial.
| geometric mean titer | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 61.6 ± 1.3 | 57.4 ± 1.3 | 80.5 ± 1.5 |
| Day 8 | 120.3 ± 1.3 | 108.4 ± 1.4 | 78.8 ± 1.4 |
| Day 29 | 175.4 ± 1.3 | 158.7 ± 1.4 | 83.1 ± 1.5 |
| Day 180 | 106.4 ± 1.3 | 68.1 ± 1.3 | 80.5 ± 1.5 |
Serum BT50 (G2.4) through 6 months after trial drug dose was measured by HBGA assay. Blood samples were collected at different timepoints throughout the trial.
| geometric mean titer | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 69.1 ± 1.3 | 65.2 ± 1.2 | 42.0 ± 1.3 |
| Day 8 | 62.3 ± 1.2 | 68.3 ± 1.2 | 33.1 ± 1.2 |
| Day 29 | 76.0 ± 1.3 | 94.4 ± 1.2 | 40.6 ± 1.3 |
| Day 180 | 49.4 ± 1.2 | 56.6 ± 1.2 | 40.3 ± 1.3 |
The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 1.9 ± 1.2 | 1.9 ± 1.2 | 1.0 ± 1.3 |
| From Day 1 to Day 29 | 2.7 ± 1.2 | 2.7 ± 1.2 | 1.0 ± 1.3 |
| From Day 1 to Day 180 | 1.6 ± 1.2 | 1.3 ± 1.2 | 1.1 ± 1.3 |
The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 0.9 ± 1.1 | 1.1 ± 1.1 | 0.7 ± 1.1 |
| From Day 1 to Day 29 | 1.1 ± 1.1 | 1.5 ± 1.1 | 0.8 ± 1.1 |
| From Day 1 to Day 180 | 0.7 ± 1.1 | 0.9 ± 1.1 | 0.8 ± 1.1 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 14 | 17 | 1 |
| Day 8: 3-fold | 8 | 9 | 0 |
| Day 8: 4-fold | 8 | 9 | 0 |
| Day 29: 2-fold | 21 | 23 | 2 |
| Day 29: 3-fold | 10 | 12 | 1 |
| Day 29: 4-fold | 10 | 12 | 1 |
| Day 180: 2-fold | 13 | 13 | 4 |
| Day 180: 3-fold | 5 | 5 | 3 |
| Day 180: 4-fold | 5 | 5 | 3 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 4 | 8 | 0 |
| Day 8: 3-fold | 1 | 1 | 0 |
| Day 8: 4-fold | 1 | 1 | 0 |
| Day 29: 2-fold | 5 | 11 | 1 |
| Day 29: 3-fold | 1 | 5 | 0 |
| Day 29: 4-fold | 1 | 5 | 0 |
| Day 180: 2-fold | 2 | 5 | 1 |
| Day 180: 3-fold | 0 | 0 | 1 |
| Day 180: 4-fold | 0 | 0 | 1 |
GMC of nasal VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in microgram per milligram (µg/mg).
| µg/mg | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 0.2 ± 1.2 | 0.2 ± 1.3 | 0.2 ± 1.2 |
| Day 8 | 0.3 ± 1.2 | 0.3 ± 1.2 | 0.2 ± 1.2 |
| Day 29 | 0.3 ± 1.3 | 0.3 ± 1.2 | 0.2 ± 1.3 |
| Day 60 | 0.2 ± 1.2 | 0.2 ± 1.2 | 0.1 ± 1.3 |
| Day 180 | 0.1 ± 1.2 | 0.2 ± 1.2 | 0.1 ± 1.3 |
GMC of nasal VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.
| µg/mg | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers |
|---|---|---|---|
| Day 1 | 0.1 ± 1.3 | 0.1 ± 1.3 | 0.1 ± 1.2 |
| Day 8 | 0.2 ± 1.3 | 0.1 ± 1.3 | 0.1 ± 1.3 |
| Day 29 | 0.2 ± 1.3 | 0.2 ± 1.3 | 0.1 ± 1.4 |
| Day 60 | 0.1 ± 1.2 | 0.1 ± 1.3 | 0.0 ± 1.3 |
| Day 180 | 0.1 ± 1.2 | 0.1 ± 1.3 | 0.1 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 1.8 ± 1.2 | 1.3 ± 1.2 | 0.7 ± 1.2 |
| From Day 1 to Day 29 | 1.7 ± 1.2 | 1.2 ± 1.2 | 0.9 ± 1.3 |
| From Day 1 to Day 60 | 0.8 ± 1.2 | 0.8 ± 1.2 | 0.5 ± 1.3 |
| From Day 1 to Day 180 | 0.7 ± 1.2 | 0.7 ± 1.2 | 0.7 ± 1.3 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 1.3 ± 1.2 | 1.3 ± 1.2 | 0.7 ± 1.2 |
| From Day 1 to Day 29 | 1.7 ± 1.2 | 1.7 ± 1.2 | 0.7 ± 1.3 |
| From Day 1 to Day 60 | 0.6 ± 1.2 | 0.8 ± 1.2 | 0.4 ± 1.3 |
| From Day 1 to Day 180 | 0.5 ± 1.2 | 0.7 ± 1.2 | 0.5 ± 1.3 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 12 | 7 | 1 |
| Day 8: 3-fold | 6 | 4 | 0 |
| Day 8: 4-fold | 4 | 2 | 0 |
| Day 29: 2-fold | 10 | 9 | 1 |
| Day 29: 3-fold | 4 | 5 | 0 |
| Day 29: 4-fold | 4 | 4 | 0 |
| Day 60: 2-fold | 5 | 6 | 0 |
| Day 60: 3-fold | 3 | 5 | 0 |
| Day 60: 4-fold | 3 | 4 | 0 |
| Day 180: 2-fold | 7 | 5 | 1 |
| Day 180: 3-fold | 5 | 3 | 1 |
| Day 180: 4-fold | 4 | 2 | 1 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 7 | 7 | 0 |
| Day 8: 3-fold | 3 | 4 | 0 |
| Day 8: 4-fold | 1 | 4 | 0 |
| Day 29: 2-fold | 10 | 12 | 0 |
| Day 29: 3-fold | 5 | 7 | 0 |
| Day 29: 4-fold | 3 | 6 | 0 |
| Day 60: 2-fold | 3 | 8 | 0 |
| Day 60: 3-fold | 3 | 4 | 0 |
| Day 60: 4-fold | 1 | 2 | 0 |
| Day 180: 2-fold | 4 | 5 | 0 |
| Day 180: 3-fold | 3 | 4 | 0 |
| Day 180: 4-fold | 2 | 3 | 0 |
GMC of saliva VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.
| µg/mg | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| Day 1 | 0.1 ± 1.3 | 0.2 ± 1.2 | 0.1 ± 1.2 |
| Day 8 | 0.1 ± 1.2 | 0.2 ± 1.2 | 0.2 ± 1.2 |
| Day 29 | 0.2 ± 1.2 | 0.2 ± 1.2 | 0.2 ± 1.2 |
| Day 60 | 0.2 ± 1.2 | 0.2 ± 1.2 | 0.2 ± 1.1 |
| Day 180 | 0.2 ± 1.2 | 0.2 ± 1.2 | 0.2 ± 1.1 |
GMC of saliva VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.
| µg/mg | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| Day 1 | 0.1 ± 1.2 | 0.1 ± 1.2 | 0.1 ± 1.2 |
| Day 8 | 0.1 ± 1.2 | 0.1 ± 1.2 | 0.1 ± 1.1 |
| Day 29 | 0.1 ± 1.2 | 0.1 ± 1.2 | 0.1 ± 1.2 |
| Day 60 | 0.1 ± 1.2 | 0.1 ± 1.2 | 0.1 ± 1.2 |
| Day 180 | 0.1 ± 1.2 | 0.1 ± 1.2 | 0.1 ± 1.2 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 1.2 ± 1.1 | 1.2 ± 1.1 | 1.1 ± 1.1 |
| From Day 1 to Day 29 | 1.5 ± 1.1 | 1.2 ± 1.1 | 1.1 ± 1.1 |
| From Day 1 to Day 60 | 1.7 ± 1.1 | 1.2 ± 1.1 | 1.4 ± 1.2 |
| From Day 1 to Day 180 | 1.5 ± 1.2 | 1.2 ± 1.2 | 1.2 ± 1.2 |
GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| From Day 1 to Day 8 | 1.1 ± 1.1 | 1.4 ± 1.1 | 1.1 ± 1.1 |
| From Day 1 to Day 29 | 1.4 ± 1.1 | 1.6 ± 1.1 | 1.0 ± 1.1 |
| From Day 1 to Day 60 | 1.5 ± 1.1 | 1.2 ± 1.1 | 1.1 ± 1.1 |
| From Day 1 to Day 180 | 1.1 ± 1.1 | 1.2 ± 1.1 | 1.1 ± 1.2 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 8 | 5 | 0 |
| Day 8: 3-fold | 5 | 3 | 0 |
| Day 8: 4-fold | 0 | 1 | 0 |
| Day 29: 2-fold | 10 | 6 | 2 |
| Day 29: 3-fold | 5 | 0 | 0 |
| Day 29: 4-fold | 2 | 0 | 0 |
| Day 60: 2-fold | 12 | 6 | 4 |
| Day 60: 3-fold | 10 | 5 | 1 |
| Day 60: 4-fold | 6 | 1 | 0 |
| Day 180: 2-fold | 11 | 5 | 5 |
| Day 180: 3-fold | 8 | 3 | 1 |
| Day 180: 4-fold | 5 | 3 | 1 |
A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers: Mothers |
|---|---|---|---|
| Day 8: 2-fold | 2 | 9 | 0 |
| Day 8: 3-fold | 1 | 1 | 0 |
| Day 8: 4-fold | 1 | 0 | 0 |
| Day 29: 2-fold | 8 | 9 | 0 |
| Day 29: 3-fold | 3 | 4 | 0 |
| Day 29: 4-fold | 3 | 2 | 0 |
| Day 60: 2-fold | 9 | 9 | 0 |
| Day 60: 3-fold | 4 | 3 | 0 |
| Day 60: 4-fold | 3 | 0 | 0 |
| Day 180: 2-fold | 6 | 5 | 3 |
| Day 180: 3-fold | 1 | 4 | 1 |
| Day 180: 4-fold | 0 | 2 | 0 |
GMC of infant stool VP1 specific (G1.1) IgA was measured by Enzyme-linked immunosorbent assay (ELISA). Assay is measured in mg/gm.
| milligram per gram (mg/gm) | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|
| Day 1 | 0.0 ± 1.2 | 0.0 ± 1.4 | 0.1 ± 1.3 |
| Day 29 | 0.1 ± 1.4 | 0.1 ± 1.3 | 0.1 ± 1.3 |
| Day 60 | 0.1 ± 1.3 | 0.1 ± 1.4 | 0.0 ± 1.5 |
GMC of infant stool VP1 specific (G2.4) IgA was measured by ELISA. Assay is measured in mg/gm.
| mg/gm | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|
| Day 1 | 0.1 ± 1.7 | 0.0 ± 1.4 | 0.1 ± 1.7 |
| Day 29 | 0.1 ± 1.6 | 0.2 ± 1.5 | 0.1 ± 1.7 |
| Day 60 | 0.1 ± 1.6 | 0.1 ± 1.6 | 0.0 ± 1.7 |
GMFR was measured by ELISA. The fold rise was calculated per participant (infant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|
| From Day 1 to Day 29 | 3.2 ± 1.3 | 1.8 ± 1.3 | 1.4 ± 1.5 |
| From Day 1 to Day 60 | 2.8 ± 1.3 | 1.5 ± 1.3 | 1.1 ± 1.4 |
GMFR was measured by ELISA. The fold rise was calculated per infant (participant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).
| fold rise | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|
| From Day 1 to Day 29 | 1.4 ± 1.4 | 3.3 ± 1.4 | 0.7 ± 1.6 |
| From Day 1 to Day 60 | 1.1 ± 1.3 | 1.9 ± 1.3 | 0.7 ± 1.5 |
A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|
| Day 29: 2-fold | 17 | 15 | 3 |
| Day 29: 3-fold | 11 | 11 | 2 |
| Day 29: 4-fold | 9 | 9 | 1 |
| Day 60: 2-fold | 15 | 12 | 4 |
| Day 60: 3-fold | 11 | 7 | 2 |
| Day 60: 4-fold | 11 | 5 | 1 |
A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).
| Participants | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|
| Day 29: 2-fold | 12 | 15 | 1 |
| Day 29: 3-fold | 7 | 13 | 0 |
| Day 29: 4-fold | 6 | 12 | 0 |
| Day 60: 2-fold | 12 | 12 | 2 |
| Day 60: 3-fold | 6 | 9 | 1 |
| Day 60: 4-fold | 5 | 7 | 1 |
Data was not collected for this outcome measure.
No measurements were reported for this outcome.
Collected over From first dose up to 365 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 Medium Bivalent Dose: Mothers | 0/30 (0%) | 0/30 (0%) | 16/30 (53.3%) |
| Arm 2 High Bivalent Dose: Mothers | 0/30 (0%) | 0/30 (0%) | 13/30 (43.3%) |
| Arm 3 Placebo: Mothers | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Arm 4 Medium Bivalent Dose: Infants | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Arm 5 High Bivalent Dose: Infants | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Arm 6 Placebo: Infants | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Event | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/30 | 8/30 | 4/16 | 0/30 | 0/30 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 6/30 | 4/30 | 1/16 | 0/30 | 0/30 | 0/16 |
| NauseaGastrointestinal disorders | 5/30 | 6/30 | 1/16 | 0/30 | 0/30 | 0/16 |
| Malaise/FatigueGeneral disorders | 2/30 | 4/30 | 2/16 | 0/30 | 0/30 | 0/16 |
| Abdominal painGastrointestinal disorders | 1/30 | 2/30 | 2/16 | 0/30 | 0/30 | 0/16 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/30 | 2/30 | 0/16 | 0/30 | 0/30 | 0/16 |
| AnorexiaMetabolism and nutrition disorders | 0/30 | 2/30 | 1/16 | 0/30 | 0/30 | 0/16 |
| FeverGeneral disorders | 2/30 | 2/30 | 0/16 | 0/30 | 0/30 | 0/16 |
Participants included both mothers and infants. Here, the overall number of participants analyzed represents the total number of mothers and infants.
| Age, Customized(Participants) | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants | Total |
|---|---|---|---|---|---|---|---|
| 30 days to 11 months | 0 | 0 | 0 | 30 | 30 | 16 | 76 |
| 18-65 years | 30 | 30 | 16 | 0 | 0 | 0 | 76 |
| Sex: Female, Male(Participants) | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants | Total |
|---|---|---|---|---|---|---|---|
| Female | 30 | 30 | 16 | 15 | 19 | 6 | 116 |
| Male | 0 | 0 | 0 | 15 | 11 | 10 | 36 |
| Race/Ethnicity, Customized(Participants) | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants | Total |
|---|---|---|---|---|---|---|---|
| Race | 30 | 30 | 16 | 30 | 30 | 16 | 152 |
| Race/Ethnicity, Customized(Participants) | Arm 1 Medium Bivalent Dose: Mothers | Arm 2 High Bivalent Dose: Mothers | Arm 3 Placebo: Mothers | Arm 4 Medium Bivalent Dose: Infants | Arm 5 High Bivalent Dose: Infants | Arm 6 Placebo: Infants | Total |
|---|---|---|---|---|---|---|---|
| Ethnicity — Black or African American | 29 | 27 | 15 | 29 | 27 | 15 | 142 |
| Ethnicity — Others | 1 | 3 | 1 | 1 | 3 | 1 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2023 to primary completion in Dec 2024, 13 months.
Results were first posted in Apr 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VXA-G1.1-NN